<DOC>
	<DOCNO>NCT00106808</DOCNO>
	<brief_summary>The purpose study compare Muraglitazar Pioglitazone patient Type 2 Diabetes . Both safety blood sugar lower effect treatment study .</brief_summary>
	<brief_title>Study Muraglitazar Versus Pioglitazone Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Type 2 Diabetes HbA1c &gt; = 8.0 % &lt; = 12.0 % Serum triglyceride concentration &lt; = 600 mg/dL Fasting cpeptide &gt; = 1.0 ng/ml Body mass index &lt; = 41 kg/m2 Drug naive patient History MI ( myocardial infarction ) , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack ( TIA ) , cerebrovascular accident , accelerated/malignant hypertension , hypertension relate CHF ( congestive heart failure ) within six month prior screen LeadIn Phase . Women child Bearing Potential Uncontrolled hypertension , CHF define New York Heart Association ( NYHA ) Class II , III IV , exacerbation previously stable CHF ( NYHA class ) uncontrolled cardiac arrhythmia 30 day prior screen LeadIn Phase . History renal disease , bladder cancer , pulmonary disease , gastrointestinal disease , active liver disease endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>